Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

24

Revenue 2017

Daiichi Sankyo

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Daiichi Sankyo's 2012 sales performance.

Daiichi Sankyo

Enhertu to provide patients with vital targeted therapy option

Enhertu to provide patients with vital targeted therapy option

AstraZeneca and Daiichi Sankyo have received notification of acceptance concerning the supplemental Biologics License Application of Enhertu (trastuzumab deruxtecan). ... Ken Takeshita, global head, R&D at Daiichi Sankyo, added: “The results of

Enhertu trial results show significant improvement for breast cancer patients

Enhertu trial results show significant improvement for breast cancer patients The treatment, jointly developed by AstraZenca and Daiichi Sankyo, was trialled in the pivotal DESTINY-Breast04 study. ... AstraZeneca (AZ) and Daiichi Sankyo have shared positive results from the pivotal DESTINY-Breast04 trial, assessing the jointly

AstraZeneca's Enhertu receives FDA grant for priority review

AstraZeneca's Enhertu receives FDA grant for priority review AstraZeneca and Daiichi Sankyo’s jointly developed drug, Enhertu (trastuzumab deruxtecan), has received a notification of acceptance of the supplemental Biologics License Application (sBLA), alongside a grant for priority review. ... Speaking on behalf

‘Excitement’ around new data for Enhertu

‘Excitement’ around new data for Enhertu These primary data from DESTINY-Breast03 led to Enhertu – jointly developed by AstraZeneca and Daiichi Sankyo – receiving its fourth breakthrough therapy designation (BTD) in the US in September 2021 for the ... Ken Takeshita, R&D head at Daiichi

FDA grants Enhertu Breakthrough Therapy Designation in breast cancer

FDA grants Enhertu Breakthrough Therapy Designation in breast cancer Enhertu is a HER2-directed antibody drug conjugate (ADC) jointly developed by AstraZeneca and Daiichi Sankyo that has now been granted four Breakthrough Therapy Designations, including two in breast cancer. ... Ken Takeshita, Global Head, R&D, Daiichi

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...